PubMed:19759529
Annnotations
LitCoin-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-137 | Sentence | denotes | The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. |
| T2 | 138-229 | Sentence | denotes | Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission. |
| T3 | 230-462 | Sentence | denotes | However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor. |
| T4 | 463-681 | Sentence | denotes | As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor. |
| T5 | 682-890 | Sentence | denotes | Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse. |
| T6 | 891-1151 | Sentence | denotes | This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)). |
| T7 | 1152-1361 | Sentence | denotes | Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice. |
| T8 | 1362-1529 | Sentence | denotes | In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.). |
| T9 | 1530-1693 | Sentence | denotes | Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity. |
| T10 | 1694-1807 | Sentence | denotes | However, unlike these latter, SSR103800 did not produce catalepsy (retention on the bar test) up to 30 mg/kg p.o. |
| T11 | 1808-2080 | Sentence | denotes | Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs. |
LitCoin-entities-OrganismTaxon-PD
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| T1 | 132-136 | OrganismTaxon | denotes | mice | NCBItxid:10095|NCBItxid:10088 |
| T3 | 365-371 | OrganismTaxon | denotes | humans | NCBItxid:9605 |
| T4 | 387-391 | OrganismTaxon | denotes | idea | NCBItxid:76236 |
| T5 | 1110-1114 | OrganismTaxon | denotes | mice | NCBItxid:10095|NCBItxid:10088 |
| T7 | 1356-1360 | OrganismTaxon | denotes | mice | NCBItxid:10095|NCBItxid:10088 |
| T9 | 1505-1509 | OrganismTaxon | denotes | mice | NCBItxid:10095|NCBItxid:10088 |
LitCoin-entities
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| 6447 | 4-25 | GeneOrGeneProduct | denotes | glycine transporter-1 | NCBIGene:14664 |
| 6448 | 36-45 | ChemicalEntity | denotes | SSR103800 | -1 |
| 6449 | 132-136 | OrganismTaxon | denotes | mice | NCBITaxon:10090 |
| 6450 | 138-151 | DiseaseOrPhenotypicFeature | denotes | Schizophrenia | MESH:D012559 |
| 6451 | 202-210 | ChemicalEntity | denotes | dopamine | MESH:D004298 |
| 6452 | 279-325 | GeneOrGeneProduct | denotes | glutamate N-methyl-D-aspartate (NMDA) receptor | NCBIGene:14810 |
| 6453 | 334-347 | DiseaseOrPhenotypicFeature | denotes | schizophrenic | MESH:D012559 |
| 6454 | 365-371 | OrganismTaxon | denotes | humans | NCBITaxon:9606 |
| 6455 | 448-461 | GeneOrGeneProduct | denotes | NMDA receptor | NCBIGene:14810 |
| 6456 | 667-680 | GeneOrGeneProduct | denotes | NMDA receptor | NCBIGene:14810 |
| 6457 | 697-718 | GeneOrGeneProduct | denotes | glycine transporter-1 | NCBIGene:14664 |
| 6458 | 720-725 | GeneOrGeneProduct | denotes | GlyT1 | NCBIGene:14664 |
| 6459 | 746-755 | ChemicalEntity | denotes | SSR103800 | -1 |
| 6460 | 782-795 | GeneOrGeneProduct | denotes | NMDA receptor | NCBIGene:14810 |
| 6461 | 823-830 | ChemicalEntity | denotes | glycine | MESH:D005998 |
| 6462 | 853-866 | GeneOrGeneProduct | denotes | NMDA receptor | NCBIGene:14810 |
| 6463 | 972-981 | ChemicalEntity | denotes | SSR103800 | -1 |
| 6464 | 1020-1033 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | MESH:D006948 |
| 6465 | 1072-1083 | ChemicalEntity | denotes | amphetamine | MESH:D000661 |
| 6466 | 1088-1094 | ChemicalEntity | denotes | MK-801 | MESH:D016291 |
| 6467 | 1110-1114 | OrganismTaxon | denotes | mice | NCBITaxon:10090 |
| 6468 | 1120-1128 | GeneOrGeneProduct | denotes | NMDA Nr1 | NCBIGene:14810 |
| 6469 | 1141-1144 | GeneOrGeneProduct | denotes | DAT | NCBIGene:13162 |
| 6470 | 1172-1181 | ChemicalEntity | denotes | SSR103800 | -1 |
| 6471 | 1209-1222 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | MESH:D006948 |
| 6472 | 1254-1267 | GeneOrGeneProduct | denotes | NMDA receptor | NCBIGene:14810 |
| 6473 | 1280-1286 | ChemicalEntity | denotes | MK-801 | MESH:D016291 |
| 6474 | 1322-1335 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | MESH:D006948 |
| 6475 | 1339-1347 | GeneOrGeneProduct | denotes | NMDA Nr1 | NCBIGene:14810 |
| 6476 | 1356-1360 | OrganismTaxon | denotes | mice | NCBITaxon:10090 |
| 6477 | 1375-1384 | ChemicalEntity | denotes | SSR103800 | -1 |
| 6478 | 1402-1415 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | MESH:D006948 |
| 6479 | 1427-1438 | ChemicalEntity | denotes | amphetamine | MESH:D000661 |
| 6480 | 1464-1484 | GeneOrGeneProduct | denotes | dopamine transporter | NCBIGene:13162 |
| 6481 | 1486-1489 | GeneOrGeneProduct | denotes | DAT | NCBIGene:13162 |
| 6482 | 1505-1509 | OrganismTaxon | denotes | mice | NCBITaxon:10090 |
| 6483 | 1559-1570 | ChemicalEntity | denotes | haloperidol | MESH:D006220 |
| 6484 | 1586-1596 | ChemicalEntity | denotes | olanzapine | MESH:C076029 |
| 6485 | 1598-1607 | ChemicalEntity | denotes | clozapine | MESH:D003024 |
| 6486 | 1612-1624 | ChemicalEntity | denotes | aripiprazole | MESH:C094645 |
| 6487 | 1679-1692 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | MESH:D006948 |
| 6488 | 1724-1733 | ChemicalEntity | denotes | SSR103800 | -1 |
| 6489 | 1750-1759 | DiseaseOrPhenotypicFeature | denotes | catalepsy | MESH:D002375 |
| 6490 | 1846-1851 | GeneOrGeneProduct | denotes | GlyT1 | NCBIGene:14664 |
| 6491 | 1863-1872 | ChemicalEntity | denotes | SSR103800 | -1 |
| 6492 | 1983-1995 | ChemicalEntity | denotes | dopaminergic | MESH:D004298 |
LitCoin_Mondo
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 138-151 | DiseaseOrPhenotypicFeature | denotes | Schizophrenia | 0005090 |
LitCoin-GeneOrGeneProduct-v0
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 4-23 | GeneOrGeneProduct | denotes | glycine transporter |
| T2 | 26-35 | GeneOrGeneProduct | denotes | inhibitor |
| T3 | 94-98 | GeneOrGeneProduct | denotes | like |
| T4 | 132-136 | GeneOrGeneProduct | denotes | mice |
| T5 | 161-170 | GeneOrGeneProduct | denotes | initially |
| T6 | 260-274 | GeneOrGeneProduct | denotes | antagonists of |
| T7 | 279-288 | GeneOrGeneProduct | denotes | glutamate |
| T8 | 300-309 | GeneOrGeneProduct | denotes | aspartate |
| T9 | 311-315 | GeneOrGeneProduct | denotes | NMDA |
| T10 | 317-325 | GeneOrGeneProduct | denotes | receptor |
| T11 | 348-352 | GeneOrGeneProduct | denotes | like |
| T12 | 448-461 | GeneOrGeneProduct | denotes | NMDA receptor |
| T13 | 487-494 | GeneOrGeneProduct | denotes | growing |
| T14 | 606-614 | GeneOrGeneProduct | denotes | activity |
| T15 | 643-648 | GeneOrGeneProduct | denotes | via a |
| T16 | 667-680 | GeneOrGeneProduct | denotes | NMDA receptor |
| T17 | 688-692 | GeneOrGeneProduct | denotes | them |
| T18 | 697-716 | GeneOrGeneProduct | denotes | glycine transporter |
| T19 | 720-725 | GeneOrGeneProduct | denotes | GlyT1 |
| T20 | 727-737 | GeneOrGeneProduct | denotes | inhibitors |
| T21 | 782-795 | GeneOrGeneProduct | denotes | NMDA receptor |
| T22 | 853-866 | GeneOrGeneProduct | denotes | NMDA receptor |
| T23 | 953-957 | GeneOrGeneProduct | denotes | like |
| T24 | 1110-1114 | GeneOrGeneProduct | denotes | mice |
| T25 | 1120-1124 | GeneOrGeneProduct | denotes | NMDA |
| T26 | 1125-1128 | GeneOrGeneProduct | denotes | Nr1 |
| T27 | 1189-1191 | GeneOrGeneProduct | denotes | mg |
| T28 | 1201-1208 | GeneOrGeneProduct | denotes | blocked |
| T29 | 1223-1230 | GeneOrGeneProduct | denotes | induced |
| T30 | 1254-1267 | GeneOrGeneProduct | denotes | NMDA receptor |
| T31 | 1268-1278 | GeneOrGeneProduct | denotes | antagonist |
| T32 | 1339-1343 | GeneOrGeneProduct | denotes | NMDA |
| T33 | 1344-1347 | GeneOrGeneProduct | denotes | Nr1 |
| T34 | 1356-1360 | GeneOrGeneProduct | denotes | mice |
| T35 | 1365-1373 | GeneOrGeneProduct | denotes | contrast |
| T36 | 1416-1423 | GeneOrGeneProduct | denotes | induced |
| T37 | 1464-1484 | GeneOrGeneProduct | denotes | dopamine transporter |
| T38 | 1496-1504 | GeneOrGeneProduct | denotes | knockout |
| T39 | 1505-1509 | GeneOrGeneProduct | denotes | mice |
| T40 | 1517-1519 | GeneOrGeneProduct | denotes | mg |
| T41 | 1576-1584 | GeneOrGeneProduct | denotes | atypical |
| T42 | 1659-1662 | GeneOrGeneProduct | denotes | all |
| T43 | 1778-1781 | GeneOrGeneProduct | denotes | bar |
| T44 | 1782-1786 | GeneOrGeneProduct | denotes | test |
| T45 | 1797-1799 | GeneOrGeneProduct | denotes | mg |
| T46 | 1823-1831 | GeneOrGeneProduct | denotes | findings |
| T47 | 1846-1851 | GeneOrGeneProduct | denotes | GlyT1 |
| T48 | 1852-1861 | GeneOrGeneProduct | denotes | inhibitor |
| T49 | 1897-1901 | GeneOrGeneProduct | denotes | like |
| T50 | 2008-2013 | GeneOrGeneProduct | denotes | has a |
| T51 | 2014-2021 | GeneOrGeneProduct | denotes | reduced |
| T52 | 2022-2026 | GeneOrGeneProduct | denotes | side |
LitCoin-GeneOrGeneProduct-v2
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 4-23 | GeneOrGeneProduct | denotes | glycine transporter |
| T2 | 26-35 | GeneOrGeneProduct | denotes | inhibitor |
| T3 | 94-98 | GeneOrGeneProduct | denotes | like |
| T4 | 260-274 | GeneOrGeneProduct | denotes | antagonists of |
| T5 | 279-288 | GeneOrGeneProduct | denotes | glutamate |
| T6 | 300-309 | GeneOrGeneProduct | denotes | aspartate |
| T7 | 311-315 | GeneOrGeneProduct | denotes | NMDA |
| T8 | 317-325 | GeneOrGeneProduct | denotes | receptor |
| T9 | 348-352 | GeneOrGeneProduct | denotes | like |
| T10 | 448-461 | GeneOrGeneProduct | denotes | NMDA receptor |
| T11 | 667-680 | GeneOrGeneProduct | denotes | NMDA receptor |
| T12 | 697-716 | GeneOrGeneProduct | denotes | glycine transporter |
| T13 | 720-725 | GeneOrGeneProduct | denotes | GlyT1 |
| T14 | 727-737 | GeneOrGeneProduct | denotes | inhibitors |
| T15 | 782-795 | GeneOrGeneProduct | denotes | NMDA receptor |
| T16 | 853-866 | GeneOrGeneProduct | denotes | NMDA receptor |
| T17 | 953-957 | GeneOrGeneProduct | denotes | like |
| T18 | 1120-1124 | GeneOrGeneProduct | denotes | NMDA |
| T19 | 1201-1208 | GeneOrGeneProduct | denotes | blocked |
| T20 | 1254-1267 | GeneOrGeneProduct | denotes | NMDA receptor |
| T21 | 1339-1343 | GeneOrGeneProduct | denotes | NMDA |
| T22 | 1464-1484 | GeneOrGeneProduct | denotes | dopamine transporter |
| T23 | 1496-1504 | GeneOrGeneProduct | denotes | knockout |
| T24 | 1576-1584 | GeneOrGeneProduct | denotes | atypical |
| T25 | 1846-1851 | GeneOrGeneProduct | denotes | GlyT1 |
| T26 | 1852-1861 | GeneOrGeneProduct | denotes | inhibitor |
| T27 | 1897-1901 | GeneOrGeneProduct | denotes | like |
| T28 | 2014-2021 | GeneOrGeneProduct | denotes | reduced |
| T29 | 2022-2026 | GeneOrGeneProduct | denotes | side |
LitCoin-Disease-MeSH
| Id | Subject | Object | Predicate | Lexical cue | originalLabel |
|---|---|---|---|---|---|
| T1 | 138-151 | DiseaseOrPhenotypicFeature | denotes | Schizophrenia | D012559 |
| T2 | 334-347 | DiseaseOrPhenotypicFeature | denotes | schizophrenic | DISEASE |
| T3 | 1020-1033 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE |
| T4 | 1209-1222 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE |
| T5 | 1322-1335 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE |
| T6 | 1402-1415 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE |
| T7 | 1679-1692 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE |
| T8 | 1750-1759 | DiseaseOrPhenotypicFeature | denotes | catalepsy | D002375 |
LitCoin-GeneOrGeneProduct-v3
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 4-23 | GeneOrGeneProduct | denotes | glycine transporter |
| T2 | 260-274 | GeneOrGeneProduct | denotes | antagonists of |
| T3 | 279-288 | GeneOrGeneProduct | denotes | glutamate |
| T4 | 310-325 | GeneOrGeneProduct | denotes | (NMDA) receptor |
| T5 | 448-461 | GeneOrGeneProduct | denotes | NMDA receptor |
| T6 | 667-680 | GeneOrGeneProduct | denotes | NMDA receptor |
| T7 | 697-716 | GeneOrGeneProduct | denotes | glycine transporter |
| T8 | 720-725 | GeneOrGeneProduct | denotes | GlyT1 |
| T9 | 782-795 | GeneOrGeneProduct | denotes | NMDA receptor |
| T10 | 853-866 | GeneOrGeneProduct | denotes | NMDA receptor |
| T11 | 1254-1267 | GeneOrGeneProduct | denotes | NMDA receptor |
| T12 | 1464-1484 | GeneOrGeneProduct | denotes | dopamine transporter |
| T13 | 1846-1851 | GeneOrGeneProduct | denotes | GlyT1 |
LitCoin_Mondo_095
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 138-151 | DiseaseOrPhenotypicFeature | denotes | Schizophrenia | 0005090 |
LitCoin-MeSH-Disease-2
| Id | Subject | Object | Predicate | Lexical cue | ID: |
|---|---|---|---|---|---|
| T1 | 138-151 | DiseaseOrPhenotypicFeature | denotes | Schizophrenia | D012559 |
| T2 | 334-347 | DiseaseOrPhenotypicFeature | denotes | schizophrenic | DISEASE |
| T3 | 1020-1033 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE |
| T4 | 1209-1222 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE |
| T5 | 1322-1335 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE |
| T6 | 1402-1415 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE |
| T7 | 1679-1692 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE |
| T8 | 1750-1759 | DiseaseOrPhenotypicFeature | denotes | catalepsy | D002375 |
LitCoin-MONDO_bioort2019
| Id | Subject | Object | Predicate | Lexical cue | #label |
|---|---|---|---|---|---|
| T1 | 138-151 | DiseaseOrPhenotypicFeature | denotes | Schizophrenia | D012559 |
| T2 | 334-347 | DiseaseOrPhenotypicFeature | denotes | schizophrenic | DISEASE |
| T3 | 1020-1033 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE |
| T4 | 1209-1222 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE |
| T5 | 1322-1335 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE |
| T6 | 1402-1415 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE |
| T7 | 1679-1692 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE |
| T8 | 1750-1759 | DiseaseOrPhenotypicFeature | denotes | catalepsy | D002375 |
LitCoin-Chemical-MeSH-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | ID: |
|---|---|---|---|---|---|
| T1 | 4-11 | ChemicalEntity | denotes | glycine | http://purl.obolibrary.org/obo/CHEBI_57305|http://purl.obolibrary.org/obo/CHEBI_29947|http://purl.obolibrary.org/obo/CHEBI_15428 |
| T4 | 36-45 | ChemicalEntity | denotes | SSR103800 | ChemicalEntity |
| T5 | 202-210 | ChemicalEntity | denotes | dopamine | D004298|http://purl.obolibrary.org/obo/CHEBI_59905|http://purl.obolibrary.org/obo/CHEBI_18243 |
| T8 | 279-288 | ChemicalEntity | denotes | glutamate | http://purl.obolibrary.org/obo/CHEBI_29987|http://purl.obolibrary.org/obo/CHEBI_14321 |
| T10 | 289-309 | ChemicalEntity | denotes | N-methyl-D-aspartate | http://purl.obolibrary.org/obo/CHEBI_31882 |
| T11 | 311-315 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_6121|http://purl.obolibrary.org/obo/CHEBI_31882 |
| T13 | 448-452 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_6121|http://purl.obolibrary.org/obo/CHEBI_31882 |
| T15 | 667-671 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_6121|http://purl.obolibrary.org/obo/CHEBI_31882 |
| T17 | 697-704 | ChemicalEntity | denotes | glycine | http://purl.obolibrary.org/obo/CHEBI_57305|http://purl.obolibrary.org/obo/CHEBI_29947|http://purl.obolibrary.org/obo/CHEBI_15428 |
| T20 | 746-755 | ChemicalEntity | denotes | SSR103800 | ChemicalEntity |
| T21 | 782-786 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_6121|http://purl.obolibrary.org/obo/CHEBI_31882 |
| T23 | 823-830 | ChemicalEntity | denotes | glycine | http://purl.obolibrary.org/obo/CHEBI_57305|http://purl.obolibrary.org/obo/CHEBI_29947|http://purl.obolibrary.org/obo/CHEBI_15428 |
| T26 | 853-857 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_6121|http://purl.obolibrary.org/obo/CHEBI_31882 |
| T28 | 972-981 | ChemicalEntity | denotes | SSR103800 | ChemicalEntity |
| T29 | 1072-1083 | ChemicalEntity | denotes | amphetamine | D000661|http://purl.obolibrary.org/obo/CHEBI_2679 |
| T31 | 1088-1094 | ChemicalEntity | denotes | MK-801 | D016291 |
| T32 | 1120-1124 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_6121|http://purl.obolibrary.org/obo/CHEBI_31882 |
| T34 | 1141-1144 | ChemicalEntity | denotes | DAT | http://purl.obolibrary.org/obo/CHEBI_137433 |
| T35 | 1172-1181 | ChemicalEntity | denotes | SSR103800 | ChemicalEntity |
| T36 | 1254-1258 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_6121|http://purl.obolibrary.org/obo/CHEBI_31882 |
| T38 | 1280-1286 | ChemicalEntity | denotes | MK-801 | D016291 |
| T39 | 1339-1343 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_6121|http://purl.obolibrary.org/obo/CHEBI_31882 |
| T41 | 1375-1384 | ChemicalEntity | denotes | SSR103800 | ChemicalEntity |
| T42 | 1427-1438 | ChemicalEntity | denotes | amphetamine | D000661|http://purl.obolibrary.org/obo/CHEBI_2679 |
| T44 | 1464-1472 | ChemicalEntity | denotes | dopamine | D004298|http://purl.obolibrary.org/obo/CHEBI_59905|http://purl.obolibrary.org/obo/CHEBI_18243 |
| T47 | 1486-1489 | ChemicalEntity | denotes | DAT | http://purl.obolibrary.org/obo/CHEBI_137433 |
| T48 | 1559-1570 | ChemicalEntity | denotes | haloperidol | D006220|http://purl.obolibrary.org/obo/CHEBI_5613 |
| T50 | 1586-1596 | ChemicalEntity | denotes | olanzapine | D000077152|http://purl.obolibrary.org/obo/CHEBI_7735 |
| T52 | 1598-1607 | ChemicalEntity | denotes | clozapine | D003024|http://purl.obolibrary.org/obo/CHEBI_3766 |
| T54 | 1612-1624 | ChemicalEntity | denotes | aripiprazole | D000068180|http://purl.obolibrary.org/obo/CHEBI_31236 |
| T56 | 1724-1733 | ChemicalEntity | denotes | SSR103800 | ChemicalEntity |
| T57 | 1863-1872 | ChemicalEntity | denotes | SSR103800 | ChemicalEntity |
| T58 | 1983-1995 | ChemicalEntity | denotes | dopaminergic | ChemicalEntity |
LitCoin-NCBITaxon-2
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 132-136 | OrganismTaxon | denotes | mice |
| T2 | 365-371 | OrganismTaxon | denotes | humans |
| T3 | 387-391 | OrganismTaxon | denotes | idea |
| T4 | 1110-1114 | OrganismTaxon | denotes | mice |
| T5 | 1356-1360 | OrganismTaxon | denotes | mice |
| T6 | 1505-1509 | OrganismTaxon | denotes | mice |
LitCoin-training-merged
| Id | Subject | Object | Predicate | Lexical cue | #label | ID: |
|---|---|---|---|---|---|---|
| T58 | 1983-1995 | ChemicalEntity | denotes | dopaminergic | ChemicalEntity | |
| T57 | 1863-1872 | ChemicalEntity | denotes | SSR103800 | ChemicalEntity | |
| T56 | 1724-1733 | ChemicalEntity | denotes | SSR103800 | ChemicalEntity | |
| T54 | 1612-1624 | ChemicalEntity | denotes | aripiprazole | http://purl.obolibrary.org/obo/CHEBI_31236|D000068180 | |
| T52 | 1598-1607 | ChemicalEntity | denotes | clozapine | http://purl.obolibrary.org/obo/CHEBI_3766|D003024 | |
| T50 | 1586-1596 | ChemicalEntity | denotes | olanzapine | http://purl.obolibrary.org/obo/CHEBI_7735|D000077152 | |
| T48 | 1559-1570 | ChemicalEntity | denotes | haloperidol | http://purl.obolibrary.org/obo/CHEBI_5613|D006220 | |
| T47 | 1486-1489 | ChemicalEntity | denotes | DAT | http://purl.obolibrary.org/obo/CHEBI_137433 | |
| T44 | 1464-1472 | ChemicalEntity | denotes | dopamine | http://purl.obolibrary.org/obo/CHEBI_18243|http://purl.obolibrary.org/obo/CHEBI_59905|D004298 | |
| T42 | 1427-1438 | ChemicalEntity | denotes | amphetamine | http://purl.obolibrary.org/obo/CHEBI_2679|D000661 | |
| T41 | 1375-1384 | ChemicalEntity | denotes | SSR103800 | ChemicalEntity | |
| T39 | 1339-1343 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_31882|http://purl.obolibrary.org/obo/CHEBI_6121 | |
| T38 | 1280-1286 | ChemicalEntity | denotes | MK-801 | D016291 | |
| T36 | 1254-1258 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_31882|http://purl.obolibrary.org/obo/CHEBI_6121 | |
| T35 | 1172-1181 | ChemicalEntity | denotes | SSR103800 | ChemicalEntity | |
| T34 | 1141-1144 | ChemicalEntity | denotes | DAT | http://purl.obolibrary.org/obo/CHEBI_137433 | |
| T32 | 1120-1124 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_31882|http://purl.obolibrary.org/obo/CHEBI_6121 | |
| T31 | 1088-1094 | ChemicalEntity | denotes | MK-801 | D016291 | |
| T29 | 1072-1083 | ChemicalEntity | denotes | amphetamine | http://purl.obolibrary.org/obo/CHEBI_2679|D000661 | |
| T28 | 972-981 | ChemicalEntity | denotes | SSR103800 | ChemicalEntity | |
| T26 | 853-857 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_31882|http://purl.obolibrary.org/obo/CHEBI_6121 | |
| T23 | 823-830 | ChemicalEntity | denotes | glycine | http://purl.obolibrary.org/obo/CHEBI_15428|http://purl.obolibrary.org/obo/CHEBI_29947|http://purl.obolibrary.org/obo/CHEBI_57305 | |
| T21 | 782-786 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_31882|http://purl.obolibrary.org/obo/CHEBI_6121 | |
| T20 | 746-755 | ChemicalEntity | denotes | SSR103800 | ChemicalEntity | |
| T17 | 697-704 | ChemicalEntity | denotes | glycine | http://purl.obolibrary.org/obo/CHEBI_15428|http://purl.obolibrary.org/obo/CHEBI_29947|http://purl.obolibrary.org/obo/CHEBI_57305 | |
| T15 | 667-671 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_31882|http://purl.obolibrary.org/obo/CHEBI_6121 | |
| T13 | 448-452 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_31882|http://purl.obolibrary.org/obo/CHEBI_6121 | |
| T11 | 311-315 | ChemicalEntity | denotes | NMDA | http://purl.obolibrary.org/obo/CHEBI_31882|http://purl.obolibrary.org/obo/CHEBI_6121 | |
| T10 | 289-309 | ChemicalEntity | denotes | N-methyl-D-aspartate | http://purl.obolibrary.org/obo/CHEBI_31882 | |
| T8 | 279-288 | ChemicalEntity | denotes | glutamate | http://purl.obolibrary.org/obo/CHEBI_14321|http://purl.obolibrary.org/obo/CHEBI_29987 | |
| T5 | 202-210 | ChemicalEntity | denotes | dopamine | http://purl.obolibrary.org/obo/CHEBI_18243|http://purl.obolibrary.org/obo/CHEBI_59905|D004298 | |
| T4 | 36-45 | ChemicalEntity | denotes | SSR103800 | ChemicalEntity | |
| T1 | 4-11 | ChemicalEntity | denotes | glycine | http://purl.obolibrary.org/obo/CHEBI_57305|http://purl.obolibrary.org/obo/CHEBI_15428|http://purl.obolibrary.org/obo/CHEBI_29947 | |
| T21495 | 1846-1851 | GeneOrGeneProduct | denotes | GlyT1 | ||
| T12 | 1464-1484 | GeneOrGeneProduct | denotes | dopamine transporter | ||
| T87490 | 1254-1267 | GeneOrGeneProduct | denotes | NMDA receptor | ||
| T86519 | 853-866 | GeneOrGeneProduct | denotes | NMDA receptor | ||
| T9 | 782-795 | GeneOrGeneProduct | denotes | NMDA receptor | ||
| T3065 | 720-725 | GeneOrGeneProduct | denotes | GlyT1 | ||
| T7 | 697-716 | GeneOrGeneProduct | denotes | glycine transporter | ||
| T6 | 667-680 | GeneOrGeneProduct | denotes | NMDA receptor | ||
| T61861 | 448-461 | GeneOrGeneProduct | denotes | NMDA receptor | ||
| T43077 | 310-325 | GeneOrGeneProduct | denotes | (NMDA) receptor | ||
| T3 | 279-288 | GeneOrGeneProduct | denotes | glutamate | ||
| T2 | 260-274 | GeneOrGeneProduct | denotes | antagonists of | ||
| T38925 | 4-23 | GeneOrGeneProduct | denotes | glycine transporter | ||
| T50100 | 1750-1759 | DiseaseOrPhenotypicFeature | denotes | catalepsy | D002375 | |
| T64017 | 1679-1692 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE | |
| T89510 | 1402-1415 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE | |
| T5047 | 1322-1335 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE | |
| T79097 | 1209-1222 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE | |
| T70673 | 1020-1033 | DiseaseOrPhenotypicFeature | denotes | hyperactivity | DISEASE | |
| T42836 | 334-347 | DiseaseOrPhenotypicFeature | denotes | schizophrenic | DISEASE | |
| T91767 | 138-151 | DiseaseOrPhenotypicFeature | denotes | Schizophrenia | D012559 | |
| T47600 | 1505-1509 | OrganismTaxon | denotes | mice | ||
| T84282 | 1356-1360 | OrganismTaxon | denotes | mice | ||
| T57477 | 1110-1114 | OrganismTaxon | denotes | mice | ||
| T92123 | 387-391 | OrganismTaxon | denotes | idea | ||
| T77100 | 365-371 | OrganismTaxon | denotes | humans | ||
| T15033 | 132-136 | OrganismTaxon | denotes | mice |
Allie
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| SS1_19759529_2_0 | 289-309 | expanded | denotes | N-methyl-D-aspartate |
| SS2_19759529_2_0 | 311-315 | abbr | denotes | NMDA |
| SS1_19759529_4_0 | 697-718 | expanded | denotes | glycine transporter-1 |
| SS2_19759529_4_0 | 720-725 | abbr | denotes | GlyT1 |
| AE1_19759529_2_0 | SS1_19759529_2_0 | SS2_19759529_2_0 | abbreviatedTo | N-methyl-D-aspartate,NMDA |
| AE1_19759529_4_0 | SS1_19759529_4_0 | SS2_19759529_4_0 | abbreviatedTo | glycine transporter-1,GlyT1 |